First-in-class and truly innovative, it employs an immuno-oncology approach to unlock a new therapeutic frontier beyond conventional paradigms.
Objective: To aim higher in oncology with a revolutionary, scalable therapy that is low-risk and has a global impact.
Why Invest in Fraisinib?
A team led by pioneers in translational science and oncology, with deep scientific expertise, regulatory experience, and strong execution capabilities.
Giacomo Drago · Chief Executive Officer
+800%
"Scalable market opportunity: strong demand for innovative treatments in tumors resistant to conventional therapies."
● UPDATES
Fraisinib: Development Status and Validations
Robust Preclinical Data
Strong antitumor activity and limited toxicity ex vivo and in vivo in animal models → a solid foundation for clinical translation
Patents Filed
International protection for GARS1 inhibition, the Fraisinib molecule, and a platform of calix-pyrrolic-based derivative compounds.
Scientific Publications
An approach validated by studies published in peer-reviewed journals and magazines.
Fase 1 clinica pianificata
in pazienti oncologici per dimostrare sicurezza e primi segnali di efficacia.